Lv1
94 积分 2024-02-22 加入
A novel hepatocyte-targeting fluorescent probe of rhodamine analogues to detect hypochlorite in lysosomes: Design, synthesis and evaluation
4个月前
已完结
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
6个月前
已完结
Rational design of dual-agonist peptides targeting GLP-1 and NPY2 receptors for regulating glucose homeostasis and body weight with minimal nausea and emesis
6个月前
已完结
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
7个月前
已完结
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
7个月前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
7个月前
已完结
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
7个月前
已完结
A novel hepatocyte-targeting fluorescent probe of rhodamine analogues to detect hypochlorite in lysosomes: Design, synthesis and evaluation
7个月前
已完结
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
7个月前
已完结
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
1年前
已完结
皖公网安备34019202002308
